开立医疗
(300633)
| 流通市值：58.61亿 | | | 总市值：94.63亿 |
| 流通股本：2.68亿 | | | 总股本：4.33亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 480,719,375.08 | 2,308,908,666.51 | 1,459,311,230.15 | 964,264,625 |
| 营业收入 | 480,719,375.08 | 2,308,908,666.51 | 1,459,311,230.15 | 964,264,625 |
| 二、营业总成本 | 523,253,650.33 | 2,183,569,025.01 | 1,499,658,882.65 | 955,582,429.16 |
| 营业成本 | 185,354,037.41 | 877,685,277.8 | 578,416,133.46 | 365,607,950.62 |
| 税金及附加 | 5,414,489.52 | 21,269,857.24 | 8,947,942.8 | 7,406,614.04 |
| 销售费用 | 154,974,275.39 | 675,489,904.28 | 478,867,249.35 | 305,029,539.07 |
| 管理费用 | 41,227,695.58 | 146,257,636.8 | 104,951,088.87 | 68,581,275.01 |
| 研发费用 | 115,341,403.68 | 495,778,393.21 | 366,780,072.05 | 244,031,119.47 |
| 财务费用 | 20,941,748.75 | -32,912,044.32 | -38,303,603.88 | -35,074,069.05 |
| 其中:利息费用 | 934,089.38 | 4,158,721.83 | 3,453,380.04 | 2,115,943.26 |
| 其中:利息收入 | 2,645,551.61 | 35,631,786.52 | 29,219,319.98 | 18,655,631.85 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 51,340.14 | 163,727.82 | 56,125.16 | 8,877.92 |
| 加:投资收益 | 261,512.18 | 2,195,770.34 | 2,078,228.25 | 2,018,513.18 |
| 资产处置收益 | - | 30,736.87 | - | - |
| 资产减值损失(新) | - | -42,213,984.81 | -13,444,560.78 | -13,444,560.78 |
| 信用减值损失(新) | 2,178,403.46 | -12,254,268.46 | 6,170,470.06 | -609,121.89 |
| 其他收益 | 23,231,583.13 | 92,021,157.25 | 55,078,825.39 | 37,816,656.21 |
| 四、营业利润 | -16,811,436.34 | 165,282,780.51 | 9,591,435.58 | 34,472,560.48 |
| 加:营业外收入 | 253,313.12 | 1,229,754.75 | 1,264,104.56 | 1,179,759.59 |
| 减:营业外支出 | 123,868.46 | 2,321,545.33 | 1,898,288.71 | 843,800.42 |
| 五、利润总额 | -16,681,991.68 | 164,190,989.93 | 8,957,251.43 | 34,808,519.65 |
| 减:所得税费用 | -5,072,557.25 | -33,089,087.37 | -24,553,810.68 | -12,221,742.03 |
| 六、净利润 | -11,609,434.43 | 197,280,077.3 | 33,511,062.11 | 47,030,261.68 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -11,609,434.43 | 197,280,077.3 | 33,511,062.11 | 47,030,261.68 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -11,609,434.43 | 197,280,077.3 | 33,511,062.11 | 47,030,261.68 |
| 扣除非经常损益后的净利润 | -14,290,110.04 | 180,275,203.05 | 23,991,020.02 | 39,876,707.67 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.03 | 0.46 | 0.08 | 0.11 |
| (二)稀释每股收益 | -0.03 | 0.46 | 0.08 | 0.11 |
| 八、其他综合收益 | 2,090,055.92 | -3,135,975.42 | 9,759,243.34 | -3,848,775.41 |
| 归属于母公司股东的其他综合收益 | 2,090,055.92 | -3,135,975.42 | 9,759,243.34 | -3,848,775.41 |
| 九、综合收益总额 | -9,519,378.51 | 194,144,101.88 | 43,270,305.45 | 43,181,486.27 |
| 归属于母公司股东的综合收益总额 | -9,519,378.51 | 194,144,101.88 | 43,270,305.45 | 43,181,486.27 |
| 公告日期 | 2026-04-29 | 2026-04-17 | 2025-10-29 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |